Clinical Characteristics of Patients who Developed Hepatocellular Carcinoma after Hepatitis C Virus Eradication with Interferon Therapy: Current Status in Japan

Satô, Akira; Sata, Michio; Ikeda, Kenji; Kumada, Takashi; Izumi, Namiki; Asahina, Yasuhiro; Osaki, Yukio; Chayama, Kazuaki; Kaneko, Shuichi; Sakai, Akito; Onji, Morikazu; Hiasa, Yoichi; Omura, Tomohiro; Ozeki, Itaru; Yokosuka, Osamu; Shiina, Shuichiro; Itsubo, Mariko; Nishiguchi, Shuhei; Hirano, Katsuharu; Ide, Tatsuya; Sakisaka, Shotaro; Yamasaki, Takahiro; Hidaka, Isao; Tanaka, Masatoshi; Kim, Soo Ryang; Ichida, Takafumi

doi:10.2169/internalmedicine.52.1180

Cited by 19 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies [9,10,11,12] have reported on risks for HCC development in patients with SVR who received IFN-based treatment. However, there are few reports on the recurrence of definitively treated HCC in patients with SVR, and on their long-term outcomes.…”

Section: Introductionmentioning

confidence: 99%

Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma

et al. 2016

Self Cite

View full text Add to dashboard Cite

Background and Aims: A sustained virological response (SVR) decreases the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C. We investigated the long-term outcomes of patients who developed HCC after achieving SVR with interferon therapy. Patients: Of 75 patients who developed HCC after SVR, 40 patients underwent radical therapies (SVR group). From 436 patients undergoing surgical resection for hepatitis C virus-positive HCC, 80 patients were randomly chosen as a control cohort, after adjusting for age, gender, and extent of hepatic fibrosis (non-SVR group). Patients were observed for a median of 5.08 years. Results: HCC recurrence was found in 16 SVR patients and in 66 non-SVR patients. The respective HCC recurrence rates of SVR and non-SVR patients were 23 and 56% at 3 years, 42 and 77% at 5 years, and 53 and 90% at 10 years (p = 0.001). The respective overall survival rates in the SVR and non-SVR groups were 93 and 68% at 5 years, 88 and 34% at 10 years, and 53 and 21% at 15 years (p = 0.001). Conclusion: Although SVR patients had a significantly lower HCC recurrence rate than the non-SVR patients, the cumulative recurrence rate of SVR patients increased to 86% at 15 years.

show abstract

Section: Introductionmentioning

confidence: 99%

Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are a number of publications suggesting that the rate of HCC may be as high as 5% in patients experiencing an SVR. [35][36][37] Those studies are, however, primarily in Asian and European populations and do not contain significant numbers of AA. The primary risk factors for developing HCC in patients with SVR are males with genotype 1 and cirrhosis at the time of viral clearance.…”

Section: Discussionmentioning

confidence: 99%

Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans

Reddy¹,

Naylor²,

Hakim³

et al. 2015

JCTH

View full text Add to dashboard Cite

Background and Aims: African Americans (AA) historically have a low response rate to hepatitis C therapies, and there is limited information available for this patient population regarding the development and treatment of chronic hepatitis C (CHC). The aim of this study was to evaluate liver disease progression and hepatocellular carcinoma (HCC) development in AA with CHC. Methods: Between 1995 and 2008, 246 AA patients with CHC were identified from a database of patients and followed until 2012-2013 (average 8 years) or the development of HCC after 2008. Results: Viral clearance (intent to treat; sustained virus response (SVR)) was achieved in 15% of patients with interferon based therapies with or without ribavirin. AA patients who achieved an SVR (n=22) did not develop HCC or new onset cirrhosis, whereas the HCC incidence in untreated AA patients was 23% (51/203). Patients who achieved an SVR also had improved fibrosis, as defined by the AST Platelet Ratio Index (APRI) and Fibrosis-4 (FIB-4) score, relative to nonresponders and untreated patients. Conclusions: The severity of liver disease at the first visit (except for cirrhosis) correlated with the development of HCC, but because of the overlap in values between patients, these measurements were not useful for predicting individual risk. Since cirrhosis at the first visit was not a predictive factor, treatment with newer antiviral therapies is the best option for reducing the incidence of advanced liver disease and its harmful outcomes in the AA population.

show abstract

“…Nationwide data reveal that 2.4% (109/4,542) of Japanese patients who achieved SVR developed liver cancer during an observation period of approximately 5.5 years [15]. The longest interval between SVR and cancer onset was more than 15 years.…”

Section: α-Fetoprotein (Afp)mentioning

confidence: 99%

Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Who Achieved Sustained Virological Response

2016

Liver Cancer

View full text Add to dashboard Cite

Clinical Characteristics of Patients who Developed Hepatocellular Carcinoma after Hepatitis C Virus Eradication with Interferon Therapy: Current Status in Japan

Cited by 19 publications

References 31 publications

Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma

Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma

Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans

Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Who Achieved Sustained Virological Response

Contact Info

Product

Resources

About